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Wound fluid contains several proteinases that are
important in the repair process. In this study, we
analyzed caseinolytic activity in wound fluid obtained
from acute (burn) wounds. Caseinolytic activity in
wound fluid increased markedly 2 d after injury and
appeared on casein zymographs as a series of bands or
a smear ranging from 30 to 100 kDa. Most of the
enzyme activity was inhibited by the synthetic human
neutrophil elastase inhibitor MDL 27,367 but not by
the naturally occurring inhibitor of elastase, human
secretory leukoproteinase inhibitor. Fractionation of
wound fluid indicated that a single enzyme accounted
for µ80% of the caseinolytic activity. This enzyme
Wound healing is a coordinated process involvingtissue degradation and regeneration. Excessivedestruction of extracellular matrix molecules byproteinases has been implicated as a contributingfactor in the failure of wounds to heal (Falanga
et al, 1994). Because control of wound proteinases may provide a
therapeutic strategy to promote healing, identifying the proteinases
that participate in repair has become a major focus of wound healing
research. One approach to accomplishing this goal is analysis of wound
fluid (Wysocki and Grinnell, 1990; Kirsner et al, 1993; Tarnuzzer and
Schultz, 1996). Wound fluid contains a mixture of plasma components
such as the adhesion proteins fibronectin and vitronectin (Grinnell
et al, 1992) and locally secreted substances such as proteinases (see
below) and growth factors (Alper et al, 1985; Matsuoka and Grotendorst,
1989; Cooper et al, 1994).
A wide array of proteinases have been identified in wound fluid.
These include matrix metalloproteinases (MMP) (interstitial collagenase,
stromelysin, and gelatinases) (Matsubara et al, 1991; Agren et al, 1992;
Young and Grinnell, 1994) and serine proteinases, e.g., plasmin and
plasminogen activator (Palolahti et al, 1993; Stacey et al, 1993).
Gelatinases (MMP-2 and MMP-9) occur at particularly high levels in
wound fluid from chronic leg ulcers (Wysocki et al, 1993; Bullen et al,
1995; Yager et al, 1996; Weckroth et al, 1996), and elastase has been
identified as the enzyme in wound fluid responsible for fibronectin
degradation (Grinnell and Zhu, 1994, 1996; Rao et al, 1995).
Palolahti et al (1993) reported that chronic wound fluid contains
elevated levels of a caseinolytic activity although they did not identify
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degraded the elastase substrate methoxysuccinyl-ala-
ala-pro-val-p-nitroanilide at a slow rate. The above
findings suggested that the enzyme responsible for
caseinolytic activity might be proteinase 3, an elastase-
related enzyme whose physiologic functions are poorly
understood. Consistent with the above possibility, we
found that monoclonal antibodies against proteinase 3
removed caseinolytic activity from wound fluid, and
that purified proteinase 3 had a similar caseinolytic
profile and inhibitor sensitivity to burn fluid. Key words:
burn injury/elastase/wound healing. J Invest Dermatol 110:67–
71, 1998
the enzyme(s) responsible for the activity. Recently, we noticed that
acute wound fluid also contains substantial caseinolytic activity. We
have now identified the enzyme responsible for this activity as proteinase
3 (PR-3), an elastase-related serine proteinase whose physiologic
functions are poorly understood (Campanelli et al, 1990; Rao et al,
1991). Details are reported herein.
MATERIALS AND METHODS
Materials Human neutrophil PR-3 was purchased from Athens Research and
Technology (Athens, GA). Human neutrophil elastase (specific activity 5 20
units per mg) and methoxysuccinyl-ala-ala-pro-val-p-nitroanilide (Cat#
454454) were from Calbiochem (San Diego, CA). Recombinant human
secretory leukocyte proteinase inhibitor was from R&D Systems (Minneapolis,
IN). Rabbit anti-human fibronectin antibody was prepared in our laboratory.
Protein G agarose was purchased from Boehringer (Indianapolis, IN). Mouse
monoclonal anti-PR-3 antibody (CLB-ANCA 12.8) was purchased from
Research Diagnostics (Flanders, NJ). Aprotinin and casein were purchased from
Sigma (St. Louis, MO). Specific elastase inhibitor MDL 27,367 (MDL) (Mehdi
et al, 1990) was a gift from Hoechst Marion Roussel (Cincinnati, OH). Human
plasma fibronectin was obtained from the New York Blood Center.
Wound fluid This research project was approved by the University Institu-
tional Review Board. Informed consent was obtained for all procedures.
Samples of burn fluid were from four patients whose burn wounds included
an extremity. Sampling of burn fluid was initiated 4–8 h after injury (day 0)
and continued at 48–72 h intervals. Collections were carried out over 4 h
periods during which time patient extremities were enclosed in a sterile glove
held in place with a noncompressive cling wrap. Wound fluid samples were
centrifuged at 22,000 3 g (Beckman J2–21 M, 20 rotor, Beckman, Fullerton,
CA) for 15 min at 22°C. Wound fluid supernatants were frozen in liquid N2
and stored at –70°C until used.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and immunoblotting SDS-PAGE and immunoblotting were carried
out as described previously (Grinnell and Zhu, 1994, 1996). Briefly, samples
for SDS-PAGE were dissolved in reducing sample buffer containing 62.5 mM
Tris, 1% SDS, 10% glycerol, 0.01% bromophenol blue, pH 6.8, and 5%
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Figure 1. Burn fluid shows increased caseinolytic activity and intact
fibronectin during the first few days after injury. Samples (60 µg) of blister
fluid (B) and burn fluid collected on the days indicated were (a) subjected to
casein zymography or (b) immunoblotted with an antibody against fibronectin.
Purified human fibronectin (FN) (0.2 µg) was used as a standard for
immunoblotting.
Figure 2. The elastase inhibitor MDL blocks caseinolytic activity in
burn fluid. Samples (75 µg) of burn fluid (day 3) were subjected to casein
zymography. MDL (100 µM) or aprotinin (0.2 mg per ml) were added to the
reaction buffer where indicated.
mercaptoethanol, and subjected to electrophoresis on 7.5% acrylamide mini-
gel (Bio-Rad Mini-Protein apparatus, Bio-Rad, Richmond, CA) at 22°C for
45 min at 200 V.
For immunoblotting, polypeptides separated by SDS-PAGE were transferred
to nitrocellulose paper (Schleicher and Schuell, Keene, NH) by electrophoresis
at 22°C for 1 h at 100 V. The transferred proteins were incubated with
polyclonal anti-fibronectin antibodies for 2 h at 22°C followed by alkaline-
phosphatase-conjugated goat anti-rabbit IgG (Bio-Rad) for 1 h at 22°C.
Visualization was accomplished using the Bio-Rad alkaline-phosphatase substrate
kit according to the manufacturer’s instructions.
Casein zymography Samples of wound fluid were dissolved in nonreducing
sample buffer containing 62.5 mM Tris, pH 6.8, 1% SDS, 12% glycerol, and
0.01% bromophenol blue, and SDS-PAGE was carried out as above using
casein-containing acrylamide gels (7.5% acrylamide and 0.1% casein). After
electrophoresis, gels were washed twice with 2.5% Triton-X-100 for 30 min
to remove SDS, rinsed briefly with H2O, and incubated overnight at 37°C in
reaction buffer containing 50 mM Tris, 150 mM NaCl (pH 7.4). At the end
of the incubations, the gels were stained with 0.125% Commassie Brilliant blue.
Areas of proteinase activity appeared as clear zones against a dark blue
background. Images were captured using a Dage-MTI CCD72 camera (Dage,
Michigan City, IN) and analyzed with NIH Image 1.55. Data are presented in
arbitrary units.
Elastase activity Elastase activity was determined as described previously
(Grinnell and Zhu, 1994, 1996). Briefly, samples of wound fluid or chromato-
graphic fractions were incubated at 22°C in 1 ml of reaction buffer containing
0.1 M HEPES, 0.5 M NaCl, 10% dimethylsulfoxide, and 1 mM elastase
substrate (methoxysuccinyl-ala-ala-pro-val-p-nitroanilide), pH 7.5 (Nakajima
et al, 1979). After incubation for the times indicated, substrate degradation was
determined by measuring OD410 (Beckman DU-40 spectrophotometer).
Figure 3. Gel filtration chromatography shows that a single peak
contains an elastase-related enzyme and most of the caseinolytic activity.
Aliquots of the fractions from gel filtration HPLC were subjected to casein
zymography (a) (15 µl) or incubated with the elastase substrate (b, c) (10 µl).
Levels of caseinolytic activity were quantitated by image capture and computer
analysis and are expressed as arbitrary units. Substrate degradation at the times
indicated was determined by measuring OD410.
Fractionation of caseinolytic activity in wound fluid
Ammonium sulfate precipitation Saturated ammonium sulfate (500 µl) was added
dropwise to 2 ml of burn fluid (50 mg per ml) to obtain a concentration of
20% saturation. After incubation for 30 min, the sample was subjected to
centrifugation at 3000 3 g for 30 min. This procedure was repeated twice to
obtain additional fractions of 40% and 60% saturation. The pellets were washed
twice with 20%, 40%, or 60% saturated ammonium sulfate, respectively, and
dissolved in 50 µl of 20 mM Tris, pH 7.4. Protein concentrations were
determined by DC Protein Assay kit (Bio-Rad).
Gel filtration high performance liquid chromatography (HPLC) Aliquots of the 60%
ammonium sulfate precipitate (µ1 mg protein) were chromatographed on a
Protein-Pak 300SW gel filtration column (Waters, Milford, MA) using the
Waters HPLC system (Model 510) at a flow rate of 0.5 ml per min and 20 mM
Tris, 1 M NaCl, pH 7.4 buffer. Fractions were collected at 0.5 min intervals.
Ultraviolet absorption was continuously recorded at 280 nm. The fractions
were stored at 4°C.
Ion exchange HPLC Fractions from the gel filtration column that contained
caseinolytic activity were pooled and chromatographed on a Protein-Pak DEAE
8HR ion exchange column (Waters) using the Waters HPLC system (Model
510) at a flow rate of 0.2 ml per min. The gradient was 15 min of 100% buffer
A (20 mM Tris, pH 7.4) followed by 60 min of 100% buffer A to 100% buffer
B (20 mM Tris, 1 M NaCl, pH 7.4). Ultraviolet absorption was continuously
recorded at 280 nm. The fractions were stored at 4°C.
Immunoprecipitation Immunoprecipitation of PR-3 was carried out as
follows. Samples of burn fluid (300 µg) were preincubated with protein G
agarose (50 µl) for 30 min at 4°C followed by centrifugation for 20 s at
12,000 3 g to preclear any proteins that nonspecifically adsorb to the beads.
Supernatants were then incubated with anti-PR-3 monoclonal antibody CLB-
ANCA 12.8 (1:10, 0.2 mg per ml) or mouse IgG (1:10, 0.2 mg per ml) for
1.5 h and then protein G agarose (50 µl) for 1 h. The complex was collected
by centrifugation for 20 s at 12,000 3 g and washed three times with Tris-
buffered saline (20 mM Tris, pH 7.5, 150 mM NaCl). The beads were extracted
with non-reducing sample buffer containing 62.5 mM Tris, pH 6.8, 1% SDS,
12% glycerol, and 0.01% bromophenol blue.
RESULTS
Caseinolytic activity in acute (burn) wound fluid increases
during the first 2 d after injury Figure 1a shows the profile of
caseinolytic activity detected by casein zymography of burn fluid
samples collected sequentially from a single patient. In blister fluid (B)
and time 0 burn fluid (collected starting 4–6 h after injury), we detected
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Figure 4. The caseinolytic profile of purified PR-3 resembles the
caseinolyic profile of burn fluid. Samples of burn fluid (BF, day 3) (75 µg)
or purified PR-3 as indicated were subjected to casein zymography. In (b),
MDL (100 µM) was added to the reaction buffer.
a band at µ70 kDa. Beginning at day 2 after injury, a large number
of additional caseinolytic bands became evident. These bands sometimes
were seen individually, but often occurred as a smear from 30 to
100 kDa. After day 2, the overall caseinolytic profile remained relatively
constant although there was some variation in the intensity of the
bands. Similar results were observed with burn fluid samples obtained
from three other patients.
It should be noted that the overall protein composition of all the
burn fluid samples including blister fluid resembled plasma (Young and
Grinnell, 1994). Also, a similar profile of caseinolytic enzyme activity
was detected in wound fluid collected from patients with venous stasis
ulcers (data not shown).
The elastase inhibitor MDL 27,367 blocks burn fluid caseinolytic
activity Because zymographs depend on running SDS-PAGE under
non-reducing conditions, the correspondence between molecular size
and migration is undependable. Moreover, complexes between pro-
teinases and their inhibitors often resist dissociation by SDS sample
buffer. Therefore, the caseinolytic profile shown in Fig 1a could have
resulted from one or several enzymes.
To learn more about the identity of the proteinase(s) responsible for
caseinolytic activity in burn wound fluid, experiments were carried
out using proteinase inhibitors. For these experiments, we analyzed
burn fluid obtained on day 3. Preliminary results indicated that
inhibitors of trypsin-like and chymotrypsin-like serine proteinases,
leupeptin, and chymostatin, had no effect on caseinolysis. As shown
in Fig 2, however, most of the caseinolytic activity was blocked by
MDL (100 µM), an inhibitor of human neutrophil elastase. In addition,
a caseinolytic band at µ30 kDa (Fig 2, arrow) was found to be inhibited
both by MDL and by aprotinin (0.2 mg per ml). Inhibition by MDL
suggested that the enzyme(s) responsible for caseinolytic activity in
burn fluid might be elastase.
Burn fluid fibronectin appears to be intact Previously, it has
been shown that unregulated levels of elastase in wound fluid results
in fibronectin degradation (Rao et al, 1995; Grinnell and Zhu, 1996).
As shown in Fig 1b, however, no degradation of fibronectin was
observed in the burn fluid samples. Fibronectin was absent from blister
fluid, presumably bound to degraded matrix (i.e., gelatin), but could
be detected in time 0 burn fluid (µ6 h) postburn and reached maximal
levels by 2–4 d. These results indicated that if elastase or an elastase-
like enzyme was present in the wound fluid samples, the enzyme
concentration was probably too low to have a detectable effect on
fibronectin.
Partial purification indicates that a single elastase-related
enzyme accounts for most of the caseinolytic activity in burn
fluid To determine whether one or several enzymes were responsible
Figure 5. The inhibitor SLPI selectively blocks the caseinolytic activity
of human neutrophil elastase but not PR-3 or burn fluid. Samples of
burn fluid (75 µg) (BF, day 3), the peak fraction (10 µl) from DEAE HPLC
(F), purified PR-3 or human neutrophil elastase (HNE) as indicated were
subjected to casein zymography. In (b), recombinant SLPI (4 µg per ml) was
added to the reaction buffer.
for caseinolysis, samples of burn fluid were subjected to fractionation
using a combination of ammonium sulfate precipitation followed by
gel filtration and ion-exchange HPLC. Caseinolytic activity was found
mostly in the 60% ammonium sulfate fraction. Gel filtration HPLC of
this fraction typically resulted in two protein peaks of comparable size.
Based on the column calibration, the first peak corresponded to
µ165 kDa, whereas the second peak corresponded to µ55 kDa (data
not shown). As shown in Fig 3a, both peaks exhibited caseinolytic
activity although most of the activity (µ80%) was in the second peak.
Because caseinolytic activity was inhibited by the elastase inhibitor
MDL (see Fig 2), the gel filtration HPLC fractions also were tested
for in vitro elastase activity using the elastase-specific substrate (methoxy-
succinyl-ala-ala-pro-val-p-nitroanilide). Figure 3b shows that enzyme
activity could be detected after a 1 h assay period, but was associated
with the minor peak of caseinolytic activity. In longer assays (2–3 d),
however, a second peak of enzyme activity also became evident as
shown in Fig 3c. The slower developing peak of in vitro enzyme
activity co-migrated with the majority of caseinolytic activity.
When the second peak from the gel filtration HPLC column, which
contained most of the caseinolytic activity, was further fractionated by
ion-exchange HPLC, several protein peaks eluted from the column,
but a single peak contained all of the caseinolytic activity and the slow
developing elastase-like activity (data not shown) (see Fig 5).
Biochemical and immunologic studies identify the elastase-
related enzyme in burn fluid as PR-3 The above results were
consistent with the idea that a single enzyme related to elastase was
responsible for most of the caseinolytic activity in wound fluid. We
therefore considered the possibility that this activity might correspond
to PR-3. PR-3 is a 29 kDa, elastase-like serine proteinase that has
been reported to degrade methoxysuccinyl-ala-ala-pro-val-p-nitroanil-
ide with a substantially lower catalytic efficiency than neutrophil elastase
(Rao et al, 1991).
Figure 4a shows that on casein zymographs, purified PR-3 migrated
as a smear of activity comparable with that observed with burn fluid,
except the µ30 kDa band present in burn fluid (arrow) was absent
from PR-3. Figure 4b shows that addition of MDL substantially
inhibited the caseinolytic activity of PR-3.
Another distinction between elastase and PR-3 is sensitivity to
human secretory leukoproteinase inhibitor (SLPI), which inhibits
human neutrophil elastase but not PR-3 (Rao et al, 1991, 1993).
Figure 5 compares the activity of PR-3, human neutrophil elastase
(HNE), burn fluid (BF), and partially purified burn fluid caseinolytic
enzyme (F) in the absence (Fig 5a) and presence (Fig 5b) of 4 µg
recombinant SLPI per ml. Unlike the multiple bands typical of PR-3,
human neutrophil elastase migrated in casein zymography as two
discrete bands, one of which was the µ30 kDa band (Fig 5a, arrowhead).
Burn fluid contained both the smear and the µ30 kDa band, whereas
partially purified burn fluid caseinolytic enzyme contained only the
smear. In the presence of SLPI, human neutrophil elastase activity and
the µ30 kDa component in burn fluid were inhibited (Fig 5b), but
not the smear of caseinolytic activity associated with PR-3 or burn fluid.
Parallel studies carried out in vitro gave similar results as above. That
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Figure 6. SLPI inhibition of in vitro enzyme activity indicates that burn fluid contains a mixture of PR-3 and elastase. Samples of burn fluid (day 3)
(100 µg) (a), PR-3 (200 ng) (b), or human neutrophil elastase (4 ng) (c) were incubated with the elastase substrate. Recombinant SLPI (0.8 µg per ml) was added
to the reaction buffer where indicated. Substrate degradation was determined at the time indicated by measuring OD410.
Figure 7. Most caseinolytic activity can be cleared from burn fluid by
immunoprecipitation with anti-PR-3 antibodies. Samples (500 µg) of
burn fluid (BF, day 3) were pretreated with protein G agarose and then the
supernatants were incubated with the monoclonal antibody against PR-3 (1:10,
0.2 mg per ml) (ANCA) or control mouse IgG (1:10, 0.2 mg per ml) (IgG)
followed by protein G agarose. Aliquots of the pellets from the pretreatment
(P1) and antibody/IgG (P2) incubations and the supernatants (S) after antibody/
IgG treatment were subjected to casein zymography.
is, SLPI completely inhibited degradation of the elastase substrate by
human neutrophil elastase (Fig 6c), but had no effect on degradation
of the elastase substrate by PR-3 (Fig 6b). As shown in Fig 6a, SLPI
inhibited activity associated with burn fluid by about 50% suggesting
that burn fluid contained a mixture of PR-3 and elastase.
Finally, experiments were carried out using an antibody against PR-
3. Figure 7 shows that most of the caseinolytic activity in burn fluid
was pelleted with anti-PR-3 monoclonal antibody ANCA 12.8 and
protein-G agarose (P2), whereas little activity pelleted with protein-G
agarose alone (P1) or with control IgG.
DISCUSSION
Palolahti et al. (1993) reported that chronic wound fluid contains
elevated levels of a caseinolytic activity although they did not identify
the enzyme(s) responsible for the activity. As shown in this study, acute
wound fluid also contains caseinolytic activity, whose timing of
appearance resembles that of the metalloproteinase MMP-9 described
previously (Young and Grinnell, 1994).
In the current studies, we identify the enzyme responsible for the
majority of the caseinolytic activity as PR-3. Evidence implicating
PR-3 as the cause of caseinolytic activity in wound fluid included
inhibition of activity by MDL but not SLPI, slow degradation of a
specific elastase substrate, and immunoprecipitation with a PR-3-
specific monoclonal antibody. Moreover, the appearance of purified
PR-3 on casein zymography—a smeared band between 40 and
100 kDa—resembled the SLPI-insensitive caseinolytic profile obtained
with burn fluid. Why PR-3, a µ29 kDa monomer (Campanelli et al,
1990), should run as a higher molecular weight complex in casein
zymography remains to be determined.
In addition to the caseinolytic activity attributed to PR-3, a second
component on casein zymographs was evident at µ30 kDa. This
component migrated similarly as the smaller band of human neutrophil
elastase activity. The µ30 kDa-associated activity was inhibited not
only by MDL, but also by SLPI. Moreover, the µ30 kDa component
was absent from casein zymographs of the HPLC gel filtration/ion
exchange peak of caseinolytic activity and was left behind when burn
fluid was immunoprecipitated by antibody against PR-3. These results
are consistent with the idea that the µ30 kDa proteinase corresponds
to a different enzyme from PR-3, most likely human neutrophil
elastase, although we have not tested this possibility directly. One
discrepancy was the ability of aprotinin to inhibit the activity of the
30 kDa band. Under routine assay conditions, most investigators have
found that aprotinin cannot inhibit elastase activity even though
aprotinin can bind to elastase (Heck et al, 1985; Fioretti et al, 1993).
Given the spatial and other constraints of the zymography assay,
however, binding of aprotinin may be sufficient to result in inhibition
of enzyme activity.
PR-3 is one of the three neutral serine proteinases present in the
azurophilic granules of neutrophils along with elastase and cathepsin
G and is secreted by degranulation after activation of neutrophils
(Baggiolini et al, 1979). Although the physiologic function of the
enzyme is not well understood, PR-3 has been identified as a target
antigen in autoimmune diseases (Campanelli et al, 1990; Mrowka et al,
1995) and may also play a role in the pathophysiology of emphysema
(Kao et al, 1988). The latter activity likely involves the ability of PR-
3 to degrade extracellular matrix molecules such as fibronectin, laminin,
elastin, and collagen type IV, which has been demonstrated in vitro
(Rao et al, 1991). In the burn wounds we were studying, however,
there did not appear to be any degradation of fibronectin, indicating
that the enzyme levels probably were too low to have a detectable effect
on fibronectin. Whether PR-3 contributes to fibronectin degradation in
chronic wounds remains to be determined.
The role of PR-3 in the wound environment may depend on the
ability of the enzyme to regulate chemokines and growth factors. PR-
3 has been shown to play a role in processing of tumor necrosis factor-
α (Robache-Gallea et al, 1995) and activation of transforming growth
factor-β (Csernok et al, 1996) and interleukin-8 (Padrines et al, 1994).
Factors such as transforming growth factor-β and interleukin-8 provide
important chemotactic and mitogenic signals for inflammatory and
mesenchymal cells critical to wound repair (Moulin, 1995; Martin,
1997), but little is known about the mechanisms by which enzymes
process these molecules during the healing process.
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